• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Michael S. Rabin, MD

Publications

  • Cooley ME, Blonquist TM, Catalano PJ, Lobach DF, Halpenny B, McCorkle R, Johns EB, Braun IM, Rabin MS, Mataoui FZ, Finn K, Berry DL, Abrahm JL.Feasibility of Using Algorithm-Based Clinical Decision Support for Symptom Assessment and Management in Lung Cancer.J Pain Symptom Manage. 2014 May 28.
    24880002
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.Cancer. 2013 Nov 1;119(21):3761-8.
    23922022
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE.Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.J Thorac Oncol. 2013 Aug;8(8):1059-68.
    23787800
  • Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.AJR Am J Roentgenol. 2013 Jul;201(1):W64-71.
    23789698
  • Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.Lung Cancer. 2013 Mar;79(3):283-8.
    23254265
  • Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.Clin Cancer Res. 2012 Aug 15;18(16):4406-14.
    22733536
  • Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA, Niland JC, Mamet R, Pisters KM.First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.J Natl Compr Canc Netw. 2012 Jul 1;10(7):847-56.
    22773800
  • Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE.Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.Cancer Imaging. 2012;12:225-35.
    22743083
  • Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.Clin Cancer Res. 2010 Dec 1;16(23):5873-82.
    21030498
  • Kim MK, Min DJ, Rabin M, Licht JD.Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants.Oncogene. 2010 Oct 18.
    20956941
  • Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ.Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.J Thorac Oncol. 2009 Nov;4(11):1389-96.
    19701107
  • Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM.Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.Cancer. 2009 Sep 15;115(18):4156-66.
    19551884
  • Allen AM, Mentzer SJ, Yeap BY, Soto R, Baldini EH, Rabin MS, Sugarbaker DJ, Bueno R.Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience.Cancer. 2008 Mar 1;112(5):1106-13.
    18286507
  • Allen AM, Rabin MS, Reilly JJ, Mentzer SJ.Unresectable adenoid cystic carcinoma of the trachea treated with chemoradiation.J Clin Oncol. 2007 Dec 1;25(34):5521-3.
    18048830
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jnne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.J Clin Oncol. 2007 Mar 1;25(7):760-6.
    17228019
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jnne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res. 2006 Jul 1;12(13):3908-14.
    16818686
  • Lo WK, vansonnenberg E, Shankar S, Morrison PR, Silverman SG, Tuncali K, Rabin M.Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session.J Vasc Interv Radiol. 2006 Jan;17(1):175-9.
    16415149
  • Johnson BE, Rabin MS.Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s.
    16000607